These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 32558402)

  • 1. Effects of Open-Label, Adjunctive Ganaxolone on Persistent Depression Despite Adequate Antidepressant Treatment in Postmenopausal Women: A Pilot Study.
    Dichtel LE; Nyer M; Dording C; Fisher LB; Cusin C; Shapero BG; Pedrelli P; Kimball AS; Rao EM; Mischoulon D; Fava M; Miller KK
    J Clin Psychiatry; 2020 Jun; 81(4):. PubMed ID: 32558402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial.
    Quiroz JA; Tamburri P; Deptula D; Banken L; Beyer U; Rabbia M; Parkar N; Fontoura P; Santarelli L
    JAMA Psychiatry; 2016 Jul; 73(7):675-84. PubMed ID: 27304433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ; Singh JB; Fedgchin M; Cooper K; Lim P; Shelton RC; Thase ME; Winokur A; Van Nueten L; Manji H; Drevets WC
    JAMA Psychiatry; 2018 Feb; 75(2):139-148. PubMed ID: 29282469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, Double-Blind, Placebo-Controlled Trial of the mGlu2/3 Negative Allosteric Modulator Decoglurant in Partially Refractory Major Depressive Disorder.
    Umbricht D; Niggli M; Sanwald-Ducray P; Deptula D; Moore R; Grünbauer W; Boak L; Fontoura P
    J Clin Psychiatry; 2020 Jul; 81(4):. PubMed ID: 32663909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study.
    Thase ME; Youakim JM; Skuban A; Hobart M; Zhang P; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
    J Clin Psychiatry; 2015 Sep; 76(9):1232-40. PubMed ID: 26301771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjunctive Brexpiprazole in Patients With Major Depressive Disorder and Irritability: An Exploratory Study.
    Fava M; Ménard F; Davidsen CK; Baker RA
    J Clin Psychiatry; 2016 Dec; 77(12):1695-1701. PubMed ID: 27379823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants.
    Thase ME; Youakim JM; Skuban A; Hobart M; Augustine C; Zhang P; McQuade RD; Carson WH; Nyilas M; Sanchez R; Eriksson H
    J Clin Psychiatry; 2015 Sep; 76(9):1224-31. PubMed ID: 26301701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Adjunctive Brexpiprazole on Sleep Disturbances in Patients With Major Depressive Disorder: An Open-Label, Flexible-Dose, Exploratory Study.
    Krystal AD; Mittoux A; Meisels P; Baker RA
    Prim Care Companion CNS Disord; 2016 Sep; 18(5):. PubMed ID: 27835722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning.
    Fava M; Okame T; Matsushima Y; Perry P; Weiller E; Baker RA
    Int J Neuropsychopharmacol; 2017 Jan; 20(1):22-30. PubMed ID: 27784751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-Dose Testosterone Augmentation for Antidepressant-Resistant Major Depressive Disorder in Women: An 8-Week Randomized Placebo-Controlled Study.
    Dichtel LE; Carpenter LL; Nyer M; Mischoulon D; Kimball A; Deckersbach T; Dougherty DD; Schoenfeld DA; Fisher L; Cusin C; Dording C; Trinh NH; Pedrelli P; Yeung A; Farabaugh A; Papakostas GI; Chang T; Shapero BG; Chen J; Cassano P; Hahn EM; Rao EM; Brady RO; Singh RJ; Tyrka AR; Price LH; Fava M; Miller KK
    Am J Psychiatry; 2020 Oct; 177(10):965-973. PubMed ID: 32660299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Open-Label Study of Adjunctive Dextromethorphan/Quinidine in Treatment-Resistant Depression.
    Wang PR; Yavi M; Lee H; Kotb Y; Shora L; Park LT; Zarate CA
    J Clin Psychopharmacol; 2023 Sep-Oct 01; 43(5):422-427. PubMed ID: 37683231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial.
    Aaronson ST; van der Vaart A; Miller T; LaPratt J; Swartz K; Shoultz A; Lauterbach M; Sackeim HA; Suppes T
    JAMA Psychiatry; 2024 Jun; 81(6):555-562. PubMed ID: 38055270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
    Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB
    Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.
    Trivedi MH; Thase ME; Fava M; Nelson CJ; Yang H; Qi Y; Tran QV; Pikalov A; Carlson BX; Marcus RN; Berman RM
    J Clin Psychiatry; 2008 Dec; 69(12):1928-36. PubMed ID: 19192475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.
    El-Khalili N; Joyce M; Atkinson S; Buynak RJ; Datto C; Lindgren P; Eriksson H
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):917-32. PubMed ID: 20175941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
    Berman RM; Fava M; Thase ME; Trivedi MH; Swanink R; McQuade RD; Carson WH; Adson D; Taylor L; Hazel J; Marcus RN
    CNS Spectr; 2009 Apr; 14(4):197-206. PubMed ID: 19407731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder.
    Bauer M; Dell'osso L; Kasper S; Pitchot W; Dencker Vansvik E; Köhler J; Jørgensen L; Montgomery SA
    J Affect Disord; 2013 Oct; 151(1):209-19. PubMed ID: 23810357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study.
    Bauer M; Pretorius HW; Constant EL; Earley WR; Szamosi J; Brecher M
    J Clin Psychiatry; 2009 Apr; 70(4):540-9. PubMed ID: 19358791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Fixed-Dose Brexpiprazole 2 mg/d as Adjunctive Treatment of Adults With Major Depressive Disorder.
    Hobart M; Skuban A; Zhang P; Augustine C; Brewer C; Hefting N; Sanchez R; McQuade RD
    J Clin Psychiatry; 2018 May; 79(4):. PubMed ID: 29873953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder.
    Mathew SJ; Gueorguieva R; Brandt C; Fava M; Sanacora G
    Neuropsychopharmacology; 2017 Dec; 42(13):2567-2574. PubMed ID: 28553836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.